title: [Cerebrovascular pharmacology of separate and combined vascular pathology of brain and heart].
abstract: The effect of nimodipine, mexidol, melatonin, afobazole, 5-hydroxy-adanamtan-2-one, and GABA conjugates with arachidonic acid and docosahexaenoyl dopamine on the cerebral circulation has been studied in intact rats and those with global transient cerebral ischemia, experimental myocardial infarction, and combined vascular pathology of brain and heart. The most pronounced vasodilation activity in rats with global transient cerebral ischemia is exhibited by nimodipine, mexidol, melatonin, afobazole, 5-hydroxy-adanamtan-2-one, and GABA-containing lipid derivatives. This effect of all these drugs (except for nimodipine) is not manifested on the background of GABA receptor blocker bicuculline. In rats with experimental myocardial infarction and combined vascular pathology of brain and heart not all of the compounds mentioned acbove with GABA-ergic mechanism of action stimulate the cerebral blood flow. Thus, both similarity and differences in cerebrovascular effects of these compounds have been found, which depend on the initial state of organism and the vascular pathology of brain and/or heart. The obtained results show good prospects for this direction of research.
authors.forename: R S
authors.initials: RS
authors.lastname: Mirzoian
authors.forename: T S
authors.initials: TS
authors.lastname: Gan'shina
authors.forename: N A
authors.initials: NA
authors.lastname: Khaĭlov
authors.forename: A V
authors.initials: AV
authors.lastname: Gnezdilova
authors.forename: D V
authors.initials: DV
authors.lastname: Maslennikov
authors.forename: I N
authors.initials: IN
authors.lastname: Kurdiumov
authors.forename: M A
authors.initials: MA
authors.lastname: Lebedeva
authors.forename: A A
authors.initials: AA
authors.lastname: Gorbunov
mesh_terms: D000218:Adamantane / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D021461:Animals, Outbred Strains; D001562:Benzimidazoles / Q000494:pharmacology; D001640:Bicuculline / Q000494:pharmacology; D002540:Cerebral Cortex / Q000098:blood supply / Q000187:drug effects* / Q000503:physiopathology; D004298:Dopamine / Q000031:analogs & derivatives / Q000494:pharmacology; D058787:GABA-A Receptor Antagonists / Q000494:pharmacology; D002546:Ischemic Attack, Transient / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008550:Melatonin / Q000494:pharmacology; D009025:Morpholines / Q000494:pharmacology; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D009553:Nimodipine / Q000494:pharmacology; D010847:Picolines / Q000494:pharmacology; D051381:Rats; D018079:Receptors, GABA / Q000378:metabolism; D013329:Structure-Activity Relationship; D014664:Vasodilation / Q000187:drug effects*; D014665:Vasodilator Agents / Q000494:pharmacology*; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives / Q000494:pharmacology
chemical_list: C410924:2-((2-morpholino)ethylthio)-5-ethoxybenzimidazole; D001562:Benzimidazoles; D058787:GABA-A Receptor Antagonists; D009025:Morpholines; D010847:Picolines; D018079:Receptors, GABA; D014665:Vasodilator Agents; C070020:emoxypine succinate; D005680:gamma-Aminobutyric Acid; D009553:Nimodipine; D008550:Melatonin; D000218:Adamantane; D004298:Dopamine; D001640:Bicuculline